D. Chapin

发表

Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.

J. Lowe, D. Helweg, J. Chen, 1991, Journal of medicinal chemistry.

Determination of vitamin A in dehydrated eggs.

D. Chapin, W. Schrenk, R. M. Consad, 1944 .

Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test

R. Kozak, E. Mohler, D. Young, 2015, Psychopharmacology.

Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.

N. Saccomano, D. Phillips, B. Koe, 1991, Journal of medicinal chemistry.

Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase.

J. Blake, C. K. Biggers, A. Villalobos, 1994, Journal of medicinal chemistry.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

K. Fennell, J. Pandit, F. Menniti, 2011, Journal of medicinal chemistry.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Spiros Liras, Anne W. Schmidt, J. Pandit, 2009, Journal of medicinal chemistry.

Design and synthesis of 1-heteroaryl-3-(1-benzyl-4-piperidinyl)propan-1-one derivatives as potent, selective acetylcholinesterase inhibitors.

A. Nagel, D. Liston, D. Chapin, 1995, Journal of medicinal chemistry.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function

F. Menniti, J. Siuciak, J. Stock, 2006, Neuropharmacology.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis

F. Menniti, J. Siuciak, C. J. Schmidt, 2006, Neuropharmacology.

Electrical Properties of Ferromagnetic CrOx (1.89 < x < 2.02)

J. Honig, J. Kafalas, D. Chapin, 1965 .

Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits

J. Siuciak, J. Stock, S. Mclean, 2007, Psychopharmacology.

Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.

M. Hajós, P. Seymour, R. Kozak, 2009, Biochemical pharmacology.

Separation of Orthohydrogen from Parahydrogen and of Paradeuterium from Orthodeuterium by Preferential Adsorption

H. L. Johnston, D. Chapin, C. M. Cunningham, 1958 .

Teaching sacrospinous colpopexy.

D. Chapin, 1997, American journal of obstetrics and gynecology.

Reduction of Brain Kynurenic Acid Improves Cognitive Function

Brooke M. Roberts, Graham V. Williams, T. Kiss, 2014, The Journal of Neuroscience.

Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo

Anne W. Schmidt, F. Menniti, M. Hajós, 2012, Journal of Pharmacology and Experimental Therapeutics.

Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.

Anabella Villalobos, Andres D. Ramirez, W. White, 2004, European journal of pharmacology.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background

J. Siuciak, C. J. Schmidt, D. Chapin, 2008, Neuropharmacology.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

J. Siuciak, D. Chapin, S. McCarthy, 2008, Psychopharmacology.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

J. Siuciak, D. Chapin, S. McCarthy, 2007, Psychopharmacology.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

P. Seymour, J. Siuciak, P. Iredale, 2007, Neuropharmacology.

5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H- pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety.

A. Villalobos, A. Nagel, D. Liston, 1995, Journal of medicinal chemistry.

5,7‐Dihydro‐3‐(2‐(1‐(phenylmethyl)‐4‐piperidinyl)ethyl)‐6H‐pyrrolo(3,2‐ f)‐1,2‐benzisoxazol‐6‐one: A Potent and Centrally‐Selective Inhibitor of Acetylcholinesterase with an Improved Margin of Safety.

Andres D. Ramirez, W. White, A. Villalobos, 1995 .

Laparoscopically assisted vaginal hysterectomy in female-to-male transsexuals.

D. Chapin, 1993, Plastic and reconstructive surgery.

Trends in Doctoral Education Fall 1968 and Future Needs.

R. Linnell, D. Chapin, 1970 .

The Very High Temperature Reactor : A Technical Summary

Doug Chapin, Scott Kiffer, Jim Nestell, 2006 .

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

R. D. Williams, W. Hoffman, F. Menniti, 2008, Journal of Pharmacology and Experimental Therapeutics.

Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test

R. Kozak, E. Mohler, D. Young, 2015, Psychopharmacology.

Calcium-Independent Phosphodiesterase Inhibitors as Putative Antidepressants: (3-(Bicycloalkoxy)-4-methoxyphenyl)-2- imidazolidinones.

D. Helweg, N. Saccomano, D. Phillips, 1991 .

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme

J. Siuciak, D. Repaske, D. Chapin, 2007, Neuropharmacology.

THE EXTREME SENSITIVITY OF PARAMAGNETIC SITES TO POISONING BY DESORBED GASES EVALUATED BY THE LOW TEMPERATURE ORTHO—PARAHYDROGEN CONVERSION

D. Chapin, M. Corrin, C. Park, 1960 .